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Pathophysiologic Findings of Irritable Bowel 
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ㅋ
The mechanism of irritable bowel syndrome (IBS) is still incompletely understood in the world although large amount of inves-
tigations have been carried out on it. There are many studies on the pathophysiology of IBS in China, which has huge amount 
of population suffering from IBS with special ethnicity and culture, including Mainland China, Hong Kong and Taiwan. We col-
lected the literatures to show the results and discuss whether there were any differences in the pathophysiologic findings be-
tween China and other countries, whether there were any differences among different subtypes and how the pathophysiology 
correlated with the manifestations of patients. Gene polymorphism, disturbances of gastrointestinal motility, visceral hyper-
sensitivity, intestinal infection and inflammation, psychological disturbances, food hypersensitivity and intolerance, and altered 
gut microflora were reviewed in this paper. Some conflicting outcomes between China and other countries were noted al-
though most of them were similar.
(J Neurogastroenterol Motil 2012;18:19-33)
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Introduction
Irritable bowel syndrome (IBS) is a common functional gas-
trointestinal disorder (FGID) mainly manifested as abdominal 
pain and correlated changed bowel habits. The chief bowel pat-
tern determines the classification of IBS subtypes, which was set 
through Rome III criteria in the recent years, including con-
stipation predominant IBS (IBS-C), diarrhea predominant IBS 
(IBS-D), mixed IBS (IBS-M) and unsubtyped IBS (IBS-U). 
Since IBS can cause substantial decline in the quality of life for 
the patients and accounts for a great amount of hospital visits and 
economic burden for society, many investigations have been done 
on the mechanisms of pathophysiology for IBS. The commonly 
stated mechanisms include genetic factors, abnormal gastro-
intestinal (GI) motility, visceral hypersensitivity, psychological 
disturbances, intestinal inflammation and so on. However, the re-
sults of these investigations have often been conflicting and no 
specific pathophysiology has been demonstrated to be certain for 
IBS.
The prevalence of IBS is reported to be 2.9%-15.6% in Asian 
countries nowadays,
1 which is nearly comparable to that in the 
Western countries. China is a great country with large amount of 
population, specific ethnicity and custom in Asia. IBS has been 
found to be common for Chinese in these years and many studies 
about IBS have been carried out recently. The results of these in-Likun Zhong and Xiaohua Hou
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vestigations on pathophysiology and differences in the results be-
tween China and other countries have not been comprehensively 
reported since most of the works in China were published in 
Chinese journals. To show the results from China and find out 
the answer, we collected the manuscripts on pathophysiology of 
IBS by searching for papers in Chinese databases and PubMed 
to comprise the studies from Mainland China, Hong Kong and 
Taiwan from 1989 to 2011. In this review, the investigations 
about pathophysiology in China would be shown from the aspects 
of genetic factors, disturbances of GI motility, visceral hyper-
sensitivity, intestinal infection and inflammation, psychological 
disturbances, food hypersensitivity and intolerance, and altered 
gut microflora, which have been frequently reported. 
Furthermore, we intended to find out if there were any differ-
ences for mechanisms among different subtypes and how the 
pathophysiology correlated to the manifestations of IBS in China.
Gene Polymorphism
Lots of familial aggregation studies and twin studies have 
suggested that genetic factors perhaps influenced the suscepti-
bility of IBS although the reports were somewhat conflicting. Up 
to now, the genes associated with serotonin, inflammation, adre-
nergic, mucosal barrier, and psychology which may play a role in 
IBS have been widely examined.
2 In China, the investigations 
about gene polymorphism are extremely limited and most of 
them are involved in serotonin and inflammation. We tried to 
find out if there were any differences in the results of gene poly-
morphism between China and other countries. The main find-
ings of the investigations from China and other countries were 
shown in Table 1.
　　Serotonin transporter (SERT) is a protein which reup-
takes 5-hydroxytryptamine (5-HT) in synaptic cleft and then re-
duces the function of 5-HT such as inducing urgency, cramps, 
diarrhea and vomiting.
3,4 The lower expression of SERT will in-
dicate higher level of 5-HT, which may be associated with bowel 
symptoms in IBS patients. The 2 well investigated polymorphism 
regions are variable number tandem repeat (VNTR) and seroto-
nin transporter linked polymorphic region (5-HTTLPR).
For the 5-HTTLPR region, there were different associa-
tions reported between the genotypes and various subtypes of 
IBS in different studies. But none of the investigations has found 
correlations between the genotypes and IBS overall which had 
not been categorized except for the study by Park.
5-15 A meta- 
analysis comprising studies involving Caucasians or Asians also 
concluded that there was no association between 5-HTTLPR 
and IBS overall.
16 The transcriptional activity of long (L) allele is 
apparently greater than short (S) allele in 5-HTTLPR for 
SERT, then L/L genotype has higher transcriptional efficacy 
than L/S and S/S genotypes. All of the studies about 
5-HTTLPR in China showed that IBS-C patients had sig-
nificantly higher frequency of L allele or L/L genotype than 
healthy individuals and patients of other subtypes.
6-10 Besides, 
Zhang and Lin
10 also exhibited that IBS-D patients had higher 
frequency of S allele and S/S genotype than healthy controls and 
patients of other subtypes. The outcomes of investigations from 
other countries exhibited some discordance. Lee et al
11 found no 
correlation between the polymorphism of 5-HTTLPR and over-
all or each subtype of IBS in Korea. While another study by Park 
et al
5 which was also from Korea showed that S/S genotype was 
more common in patients with IBS than healthy controls, espe-
cially in IBS-D subtype. The result of investigation by Kim et al
12 
from US was the same with Lee et al.
11 Yeo et al
4 found the fre-
quency of S/S genotype to be higher in female IBS-D patients 
than healthy controls in US. However, the investigations from 
Turkey by Pata et al
13 and from India by Sikander et al
14 both 
found the contradictory result that S/S genotype was more com-
mon in IBS-C than controls. Niesler et al
15 also showed that male 
IBS-D patients had lower frequency of S/S genotype than con-
trols in UK. Therefore, from the various results above, we could 
not obtain a firm conclusion about the relationship between poly-
morphism of 5-HTTLPR and IBS subtypes. But the results of 
investigations from China were almost the same for L/L geno-
type associated with IBS-C,
6-10 which was contradictory to the in-
vestigations by Pata and Sikander et al.
13,14 In addition, the ex-
planations for the conflicting phenomenon by them were also 
different. Wang et al
6 speculated that the L/L genotype for high 
expression of SERT caused 5-HT reuptake before the effects of 
5-HT were shown and then attenuated the motility and secretion 
of intestine to cause IBS-C. However, Pata et al
13 considered the 
S/S genotype responding to the low expression of SERT which 
might have caused the aggregation of 5-HT and then down- 
regulated the 5-HT receptors, therefore led to IBS-C.
Racial difference might be one of the reasons for the varia-
tions of these results since the distribution of 5-HTTLPR gene 
polymorphism varied among different races and regions. Homo-
zygous for the S allele in Asians (64% of patients) was reported to 
be markedly higher than that in Caucasians (22% of patients) in a 
meta-analysis.
16 Xie J et al
17 investigated the polymorphism re-
gions of 5-HTTLPR for healthy individuals of Han Chinese 
and found the frequencies of S allele and S/S genotype to be pre-Pathophysiologic Findings of IBS in China
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Table 1. Comparisons on Genetic Polymorphism for Irritable Bowel Syndrome in China and Other Countries
Pathway Locus First author Region Overall IBS vs control  IBS subtype vs control 
SERT 5-HTTLPR Wang et al
6 Tianjin, China  No relation L/L in IBS-C higher than control and 
IBS-D, IBS-A; L/S in IBS-D, IBS-A 
higher than IBS-C
Li et al
8 Guangdong, China  No relation L/L in IBS-C higher than control and 
IBS-D, IBS-A
Xie et al
9 Jiangxi, China No relation L/L in IBS-C higher than control 
Zhang and Lin
10 Fujian, China No relation L/L in IBS-C higher than control and 
IBS-D, IBS-A; S/S in IBS-D higher 
than control
Lee et al
11 Korea No relation No relation
Park et al
5 Korea S/S higher in IBS  S/S in IBS-D higher than control
Pata et al
13 Turkey No relation L/S in IBS-D higher than control and 
IBS-C, IBS-A; S/S in IBS-C higher 
than IBS-D, IBS-A
Sikander et al
14 India No relation S/S more common in IBS-C than 
non-S/S genotype
Kim et al
12 US No relation No relation
Yeo et al
4 US - S/S in female IBS-D higher than control 
Niesler et al
15 UK No relation S/S in male IBS-D lower than control
VNTR Wang et al
6 Tianjin, China STin2.12/10  STin2.12/12-L/L in IBS-C higher than
  higher in IBS   IBS-D, IBS-A
Li et al
8 Guangdong, China No relation No relation
Xie et al
9 Jiangxi, China No relation No relation
Zhang and Lin
10 Fujian, China No relation No relation
Pata et al
13 Turkey No relation No relation
Niesler et al
15 UK No relation No relation
IL-10 1082 G/A Wang et al
19 Tianjin, China - No relation between IBS-D and control
Santhosh et al
21 India No relation -
Gonsalkorale et al
22 UK G/G lower in IBS No relation
Van der Veek et al
23 Dutch No  relation No  relation
819 C/T Wang et al
19 Tianjin, China  - T/T and T allele in IBS-D higher than 
control
Santhosh et al
21 India No relation -
Van der Veek et al
23 Dutch No  relation No  relation
592 C/A Wang et al
19 Tianjin, China - A/A and A allele in IBS-D higher than 
control
Jiang et al
20 Guangdong, China Allele A and A/A -
 higher in IBS
Santhosh et al
21 India Allele A higher in IBS -
CNR1 AAT triplet Zhang et al
26  Guangdong, China Allele ≥10 and ≥10/≥10 No relation
 repeats   genotype higher in IBS
Park et al
28 Korea  ＞10/＞10 genotype higher ＞10/＞10 genotype in all IBS subtypes
  in IBS   higher than control
TRPV1 TRPV1 gene Zhang et al
27 Gansu, China C/C and allele C higher in IBS -
IBS, irritable bowel syndrome; SERT, serotonin transporter; 5-HTTLPR, serotonin transporter gene-linked polymorphic region; IBS-C, constipation predominant 
IBS; IBS-D, diarrhea predominant IBS; IBS-A, alternating IBS; PI-IBS, post-infectious IBS; VNTR, variable number tandem repeat; CNR1, cannabinoid receptor
1; TRPV1, transient receptor potential vanilloid type 1.
dominantly higher than the frequencies of L allele and L/L 
genotype. The result was similar to that in Korean and Japanese 
with this predominance, while different from that in Turkish, 
European and American without this predominance.
17 Therefore 
the racial difference may play a role in the gene polymorphism of 
IBS, although many other factors such as environment, habits Likun Zhong and Xiaohua Hou
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and study designs could also influence the results. In addition, 
the gender difference probably also influenced the gene poly-
morphism, since S/S genotype was found to be higher in female 
IBS-D patients
4 and lower in male IBS-D patients
15 than 
controls. The investigation by Sikander et al
14 which showed S/S 
genotype was more common in IBS-C patients included more 
male patients, while the investigations in China which showed 
higher level of L/L genotype in IBS-C patients included more fe-
male patients.
6-10
Particularly, the polymorphism has been recently shown to be 
associated with the treatment response to the drug related to 
5-HT in patients with IBS. Smeraldi et al
18 found that the effect 
of selective serotonin reuptake inhibitors (SSRIs) fluvoxamine 
was better for patients with L/L and L/S genotype than S/S 
genotype. Camilleri et al
3 reported that 5-HT3 receptor antago-
nist alosetron was better for L/L genotype in IBS-D patients. Li 
et al
8 showed that the effect of 5-HT4 agonist tegaserod was 
worst for L/L genotype. These different pharmacologic re-
sponses might indicate that genetics influenced the effect of 
drugs on patients with IBS although the underlying reasons were 
unclear.
For VNTR region, most of the investigations in China
8-10 
and all of the investigations in other countries
13,15 found no sig-
nificant difference between IBS patients and healthy adults, also 
with no difference among the subtypes. But Wang et al
6 found 
that STin2.12/10 genotype was more common in patients with 
IBS than healthy controls, and patients with IBS-C showed in-
creased frequency of STin2 VNTR 12/12 and 5-HTTLPR L/L 
genotype (12/12-L/L) than controls and other subtypes. Chen et 
al
7 showed similar result for post-infectious IBS (PI-IBS) 
patients. These 2 particular results may need further con-
firmation by more meticulous investigations with larger sample 
size.
IL-10 is an important anti-inflammatory cytokine in body. 
Therefore the genotype encoding low producer of IL-10 might 
be more prevalent in IBS patients since the infection and in-
flammation are always thought to be associated with IBS. Three 
well investigated regions for IL-10 were 1082, 819 and 592 loci 
in promoter. As mentioned in reports, 1082A, 819T and 592A 
were the lower producer alleles for IL-10 compared to 1082G, 
819C and 592C respectively, so they might predict higher preva-
lence of IBS.
19 Most studies showed IBS patients had higher fre-
quency of low producer genotypes in these regions, which would 
lead to lower level of IL-10. Wang et al
19 reported that IBS-D 
patients had higher frequency of low producer genotypes 819 
T/T and 592 A/A than healthy individuals. Higher frequency of 
low producer genotype 592A/A in patients with IBS overall was 
found in report of Jiang et al.
20 A recent investigation in India re-
ported patients with IBS overall had higher frequency of A allele 
in 592 locus, but no significant difference was found for alleles in 
819 and 1082 loci and genotypes in these 3 regions.
21 Different 
results also presented in the studies from the West. One study 
showed that the high producer 1082 G/G genotype was sig-
nificantly lower in patients with IBS overall than controls.
22 
While another study found no relationship between overall or 
each subtype of IBS and the genotypes in 1082 and 819 loci.
23 
These results suggested that the genetic alteration might contrib-
ute to the alteration of inflammatory cytokine level in some IBS 
patients, and thus affected the inflammatory state in these 
patients. In addition, there were several investigations reporting 
variation in genotypes regarding IL-10 according to ethnicity, 
with increased frequency of low producer genotype A/A or A al-
lele in Chinese group than other population.
24,25
Other 2 less investigated genes for IBS in China were asso-
ciated with cannabinoid receptor 1 (CNR1)
26 and capsaicin re-
ceptor/transient receptor potential vanilloid type 1 (TRPV1).
27 
Since the cannabinoid could affect GI function, genetic variants 
for the CNR1 were hypothesized to be associated with patho-
genesis of IBS. Zhang et al
26 found that allele ≥ 10 and ≥ 10/ 
≥ 10 genotype for AAT triplet repeats in the 3-flanking region 
of CNR1 gene were significantly higher in patients with IBS than 
controls in Han population in Guangdong. Another investigation 
involving Korean subjects also showed the similar result and 
found that the patients with CNR1 ＞ 10/ ＞ 10 genotype had 
more severe abdominal symptoms.
28 The capsaicin receptor 
TRPV1 was estimated to be related with visceral pain and hyper-
sensitivity states in IBS. The frequency of C/C genotype and C 
allele for TRPV1 gene were both reported to be higher in patients 
with IBS than healthy individuals.
27 These gene polymorphisms 
for CNR1 and TRPV1 may also be related to the susceptibility to 
IBS, which have not been reported in the West.
In conclusion, although the investigations of the gene poly-
morphism for IBS in China are limited, some of the results are 
different from those in other countries. The reason may be com-
plex, and ethnicity and gender differences probably may some-
what correlate with it. More efforts are demanded to provide spe-
cial data in China about candidate genes, which may contribute to 
future new therapy.Pathophysiologic Findings of IBS in China
23 Vol. 18, No. 1   January, 2012 (19-33)
Table 2. Studies on Gastrointestinal Motility Disturbances for Irritable Bowel Syndrome in China
First author Main finding
Lu et al
30 Longer orocecal transit time in IBS-C patients while shorter in IBS-D patients
Duan and Zhao
31 Longer total and each segmental colonic transit time in IBS-C patients
Zhang et al
39 Impaired accommodation and accelerated emptying of proximal stomach in IBS patients, with no significant difference between
IBS-D and IBS-C patients
Wang et al
33 Shorter interdigestive MMC period, with prolonged duration, greater amplitude and faster propagation velocity for the phase III
Zhao et al
34    of MMC in IBS-D patients, whereas contrary alterations in IBS-C patients; no association between DCC and abdominal pain
Chen et al
36 Increased peristaltic contraction and delayed gastrocolic reflex after meal in IBS-D patients; increased segmental movement but
decreased peristaltic contraction in IBS-C patients
Liang et al
35 Increased sigmoid colon motility at fasting state and delayed but longer gastrocolic reflex in IBS-D patients than controls and 
IBS-C patients
IBS, irritable bowel syndrome; IBS-C, constipation predominant IBS; IBS-D, diarrhea predominant IBS; MMC, migrating motor complex; DCC, discrete clustered
contraction.
Disturbances of Gastrointestinal Motility
Different results of GI motility measurements between IBS 
patients and healthy controls have been commonly reported in 
China (Table 2), which indicate that altered GI motility may con-
tribute to the pathogenesis of IBS. The dysmotility of GI tract ac-
counting for the symptoms of IBS is still in dispute.
29 However 
the clinical investigations show the association between GI mo-
tility disturbances and bowel habits of different IBS subtypes. In 
general, the findings of parameters about gut motility suggested 
that the motility increased in IBS-D patients while decreased in 
IBS-C patients. From the aspect of GI transit time, all related 
studies in China showed that either the orocecal transit time or 
the total and each segmental colonic transit time was shorter in 
IBS-D patients and longer in IBS-C patients than healthy 
controls.
30-32 The results were in agreement with those in many 
studies of other countries, although this correlation was not al-
ways consistent.
Disturbances of small bowel motility were widely reported in 
patients with IBS from various aspects in the world. In China, 
only the studies about discrete cluster contractions (DCC) and 
migrating motor complex (MMC) has been reported. The work 
by Wang and Zhao et al
33,34 showed that patients with IBS-D ex-
hibited shorter period for MMC, with prolonged duration pro-
portion, greater amplitude, higher motility index and faster prop-
agation velocity for the phase III of MMC than healthy controls, 
whereas patients with IBS-C exhibited the contrary alterations. 
Since phase III was important to the propagating movement of 
the intestine, the longer duration and greater amplitude of this 
phase was closely related to the symptom of diarrhea with quicker 
bowel movement. The duration of DCC in phase II was reported 
to be longer in patients with IBS than healthy controls, but no 
significant relationship between DCC and the episode of abdomi-
nal pain was found in Wang et al,
33 while investigations in the 
West showed that the increased frequency and duration of DCC 
were associated with abdominal pain.
29 Perhaps larger sample 
size was needed to clarify this result in China. Zhao et al
34 also ob-
served that the plasma motilin and 5-HT level were higher in 
IBS patients and fluctuated with the phase of MMC cycle, in-
dicating the association of GI hormone and motility.
For colon motility, Liang et al
35 reported that patients with 
IBS-D had stronger sigmoid colon motility, which represented as 
elevated wave amplitude and longer duration of high amplitude 
propagative bursts and higher MI at fasting state. Chen et al
36 
observed the motility of sigmoid colon by ultrasonography, and 
found that patients with IBS-D had more, while patients with 
IBS-C had less peristaltic contraction, whether at fasting or after 
meal. These 2 studies both reported that the patients with IBS-D 
had delayed but longer gastrocolic reflex after meal, which was 
not found in controls and patients with IBS-C.
35,36 Most studies 
in other countries also showed the concordant results that there 
were more colonic motility in IBS-D patients while fewer in 
IBS-C patients.
37,38
Upper GI symptoms were commonly seen in patients with 
IBS, and maybe these symptoms are somewhat correlated with 
the abnormal gastric motility. Our group investigated the accom-
modation and emptying of proximal stomach by real-time ultra-
sonography, and found that both the initial and maximal volumes 
of proximal stomach in IBS-D and IBS-C groups were lower 
than those in healthy group. This result indicated impaired ac-
commodation of proximal stomach, which might induce higher 
pressure in stomach contributing to the dyspepsia symptoms such Likun Zhong and Xiaohua Hou
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as early satiety and abdominal distention.
39 The emptying of 
proximal stomach in IBS patients was recorded to be accelerated, 
which may also be correlated with the higher pressure of stomach 
in IBS patients.
39 However, delayed gastric emptying in IBS pa-
tients have been shown in many studies of other countries,
40-42 es-
pecially in patients with dyspepsia symptoms
40 or IBS-C 
patients.
42 The variation of results between China and other 
countries may be caused by the different test methods and trial 
designs.
To summarize, various disturbances of GI motility have been 
found in different subgroups of IBS patients, which are likely to 
play an important role in bowel habits of IBS. There are still a few 
conflicting results found between China and other countries, and 
further confirmatory work is needed in China to get the truth. 
Visceral Hypersensitivity
Visceral hypersensitivity has been commonly reported as a 
pathophysiologic factor for IBS in recent years, which may play a 
role in the symptoms of IBS especially abdominal pain. Many 
studies have shown higher sensitivity to rectal balloon distention 
in IBS patients in China (Table 3). Most of the studies reported 
that the initial perception thresholds, defecation thresholds and 
pain thresholds were much lower in IBS-D patients than those in 
healthy volunteers.
43-46 But different from the consistent result in 
patients with IBS-D, there was still controversy for patients with 
IBS-C. Dong and Li et al
43,47 reported that patients with IBS-C 
had lower initial perception, defecation and pain thresholds than 
healthy controls; Xiao and Shen et al
45,46 reported no significant 
difference compared with controls; Li’s group and Zhan et al
32,44 
reported lower initial perception thresholds in IBS-C patients 
than controls without significance, but significantly higher defe-
cation thresholds than controls; Yang et al
48 even reported higher 
perception, defecation and pain thresholds than controls. Chen et 
al
49 showed that the perception thresholds of IBS patients were 
lower than controls with quick dilation test but no significant dif-
ference was noted on the slow dilation test. In conclusion, most of 
these researches above suggested higher sensation feeling in 
IBS-D patients and related lower sensation in IBS-C patients, 
and the method of dilatation might have influenced the results.
Similar to the results in China, many studies in other coun-
tries also reported decreased sensory thresholds to rectal dis-
tension in IBS patients. Moreover, enhanced perceptions to vis-
ceral stimulation were also reported in other regions of the GI 
tract in other countries. However, not all of the investigations 
showed identical results. The results for sensory thresholds were 
also found to be different among the investigations measured by 
different distension methods in the West, with lower thresholds 
for rapid phasic distensions than slow ramp distensions.
50 In ad-
dition, IBS-D patients were reported to be more sensitive than 
IBS-C patients and the different results for IBS-C patients also 
existed in the studies from other countries. In these studies, less, 
equal or higher sensitivities corresponding to rectal distension in 
IBS-C patients compared to healthy subjects have been re-
ported.
51 The different results for IBS-C patients may be related 
to the long-term high pressure of rectum for some patients with 
constipation and the variability among these patients such as diet-
ary fiber intakes and other managements.
The sensation and related symptoms of IBS patients in re-
spond to other stimulations aside from pressure stimulus have al-
so been reported in China. Li’s group
44 found that the initial and 
defecation thresholds responding to rectal distension in IBS pa-
tients decreased significantly after ice-water injected into balloon, 
especially in IBS-D patients, while cold stimulation on abdomen 
did not affect the thresholds although it could have induced the 
symptoms of IBS. This investigation indicated that hyper-
sensitivity was also related to thermal stimulation and might have 
been limited to the viscera.
44 Another study by them reported that 
the initial perception and defecation thresholds decreased after ice 
water drinking in IBS-D patients, which were negatively related 
to the symptoms.
52 These results above suggested visceral hyper-
sensitivity to mechanical and temperature stimulation might exist 
in IBS patients, and the altered sensitivity correlated with ab-
dominal symptoms. Although it remains controversial whether 
somatic sensory dysfunction exists in IBS for different results in 
various studies worldwide, most studies tend to report no sig-
nificant relationship between somatic sensitivity and IBS pati-
ents.
51,53 Lots of investigations in other countries have also dis-
played the altered visceral sensitivity correlating with GI symp-
tom severity of IBS, despite some conflicting results.
The altered cerebral response to rectal balloon distension has 
been shown in patients with IBS assessed by various techniques 
in most studies worldwide. In China, the cerebral responses as-
sessed by methods of functional magnetic resonance imaging 
(fMRI) and cerebral evoked potentials (CEP) have been re-
ported (Table 3). Yuan et al
54 showed both IBS patients and con-
trols to present exaggerated activity at the regions of anterior cin-
gulate cortex, insula, prefrontal cortex and thalamus by fMRI 
during rectal distension, while IBS patients showed enhanced ac-
tivation in insula, prefrontal cortex and thalamus than controls. 
They also found that IBS patients had more severe pain respond-Pathophysiologic Findings of IBS in China
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Table 3. Studies on Visceral Hypersensitivity for Irritable Bowel Syndrome in China
Targets First author Main findings
Intestinal sensory Dong et al
43 Lower initial perception, defecation and pain thresholds in IBS-D and IBS-C patients than controls
  response to rectal Xiao et al
45 Lower initial perception, defecation and pain thresholds in IBS-D patients than IBS-C patients and controls;
  distention  no significant difference between IBS-C patients and controls
Shen et al
46 Lower defecation threshold in IBS-D patients than IBS-C patients and controls; no significant difference 
between IBS-C patients and controls
Li et al
47 Lower perception, defecation and pain thresholds in IBS-C patients than controls
Zhan et al
32 Lower initial perception threshold in IBS-C patients than controls without significance, but significantly higher
defecation threshold than controls
Yang et al
48  Lower initial perception, defecation and pain thresholds in IBS-D patients but higher in IBS-C patients than 
controls
Li et al
44 Lower initial perception and defecation thresholds in IBS-D and IBS-A patients, which decreased after ice 
water injection; lower initial perception threshold but higher defecation threshold in IBS-C patients 
Zuo et al
52 Decreased initial perception and defecation threshold after ice water drinking in IBS-D patients with negative,
linear correlation to symptoms
Cerebral response Zuo et al
55 Shorter N1, P1, N2 latencies of CEP by rectal distention in IBS patients than controls, which decreased after 
ice water drinking
Shen et al
46 Increased activation at insula, prefrontal cortex and thalamus in IBS patients to rectal distention than controls
Yuan et al
54
MCs and 5-HT Dong et al
43  MCs at terminal ileum, ICJ, ascending colon, and VIP and SP positive nerve fibers increased in IBS patients;
MCs were close to unmyelinated nerves and plasma cells 
Wang et al
57 MCs at terminal ileum increased in IBS patients and closely surrounded NSE, SP, 5-HT and CGRP positive
nerve fibers
Wang et al
58 MCs at the terminal ileum increased in IBS patients; 5-HT at the proximal jejunum decreased in IBS-C 
patients
Yang et al
59 MCs at ICJ increased in the IBS patients 
Chen et al
60 MCs at ICJ, TRPV1 at sigmoid colon, SP at both sites increased in IBS patients, without significant difference
between IBS-D and IBS-C; TRPV1 positively correlated with abdominal pain
Wang et al
62 MCs at cecum and transverse colon increased in IBS-D patients; degranulated MCs percentage in cecum, 
transverse colon and rectum mucosa of IBS-D patients, which were higher than controls and IBS-C patients
Wang et al
63 Number and activity of MCs at rectosigmoid junction increased in IBS, correlating with symptom severity
Chen et al
61 MCs and degranulated MCs percentage at ICJ increased in IBS patients, which was higher in IBS-D than 
IBS-C patients; 5-HT concentration at ICJ increased in IBS patients, with no significant difference between 
IBS-D and IBS-C patients
Li et al
64 5-HT positive cells and 5-HT3 receptor in all sections of colon increased in IBS-D patients than controls 
Li et al
65 Number and activity of EC cells increased in IBS patients
Zhan et al
66 5-HT and 5-HIAA levels in plasma were lower at remission than active stage in IBS patients, which remained
higher than controls; 5-HT level was higher in IBS-D than IBS-C patients at active but not remission stage
Zuo et al
67 5-HT and 5-HIAA levels in plasma were higher in IBS-D patients than controls after ice water intake, but no
significant difference at fasting stage
IBS, irritable bowel syndrome; IBS-D, diarrhea predominant IBS; IBS-C, constipation predominant IBS; IBS-A, alternating IBS; CEP, cerebral evoked potentials; 
MCs, mast cells; 5-HT, 5-hydroxytryptamine; ICJ, ileocecal junction; VIP, vasoactive intestinal polypeptide; SP, substance P; NSE, neuron-specific enolase; CGRP,
calcitonin gene-related peptide; TRPV1, transient receptor potential vanilloid type 1; EC, enterochromaffin; 5-HIAA, 5-hydroxyindoleacetic acid.
ing to rectal distention than controls, which supported the associ-
ation between the altered cerebral response and pain perception in 
IBS patients.
54 Zuo et al
55 recorded the CEP to rectal balloon dis-
tension and then found specific latencies of CEP to be decreased 
in IBS patients with shorter CEP after ice water intake. The re-
sult suggested the role of visceral hypersensitivity and defects in 
visceral afferent pathway.
55 Despite contradictory results pre-
sented among different studies worldwide, most of them sug-
gested differences existed between IBS patients and healthy con-
trols in the response of brain during gut stimulation. Although 
the activated cerebral regions in respond to rectal distension var-
ied in different reports, a meta-analysis showed IBS patients had Likun Zhong and Xiaohua Hou
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consistently greater activations in the regions related to pain mod-
ulation and emotional arousal than controls by collecting re-
searches with fMRI or positron emission tomography techni-
ques. It was supposed that disturbances in central nervous system 
processing might have been involved in the pathophysiology of 
IBS.
56
Neurohumoral abnormalities have been identified in IBS pa-
tients with visceral hypersensitivity, of which mast cells (MCs) 
and 5-HT were most commonly reported. The MCs in gut in-
cluding terminal ileum,
43,57,58 ileocecal junction,
43,59-61 cecum,
60 
ascending colon,
43 transverse colon
62 and rectosigmoid junction
63 
have been reported to increase in IBS patients compared with 
health controls (Table 3). Dong et al
43 also reported apparent var-
iation of MCs existing in IBS patients. The expression of certain 
transmitters and neuropeptides such as substance P, neu-
ron-specific enolase, calcitonin gene-related peptide and 5-HT 
were reported to be elevated in IBS patients. The nerve fibers 
with the positive expression of these substances were found to 
surround MCs closely, which indicated that MCs might play an 
important role in pathophysiology of IBS through the connection 
of nerve and immune systems.
43,57 Furthermore, Chen et al
61 and 
our group
62 both reported the percentage of degranulated MCs 
in IBS patients which was higher than controls, and this percent-
age was significantly higher in IBS-D patients than that in IBS-C 
patients. The concentration of 5-HT and the number and activity 
of EC cells in colonic mucosa were always found to be elevated in 
IBS patients.
61,64,65 But Wang et al
58 showed variant levels of 
5-HT in different parts of small intestine, with significantly lower 
level of 5-HT in the proximal jejunum. For 5-HT and 5-hydrox-
yindoleacetic acid (5-HIAA) level in plasma, Zhan
66 reported 
significantly higher level in patients with IBS than controls 
whether at the active or remission stage, while Zuo et al
67 reported 
higher level in IBS-D patients than controls after ice water drink-
ing but not at fasting state. However, whether difference existed 
in the expression of MCs and 5-HT in IBS-D and IBS-C pa-
tients was controversial. Some studies reported higher level in 
IBS-D than IBS-C patients, while others reported no significant 
difference between them.
60-64 In addition, the activation percent-
age of MCs and 5-HT level were reported to be positively corre-
lated with severity of symptoms.
63,67 TRPV1 was also shown to be 
positively related to the score of abdominal pain.
60 These studies 
about relationship between symptoms of IBS and immunity ma-
terials associated with sensitivity may further support the mecha-
nism of visceral hypersensitivity in IBS.
In general, visceral hypersensitivity is involved in both the 
gut and brain in IBS patients and probably contributes to the 
symptoms of these patients. The underlying mechanisms of hy-
persensitivity have not been clear yet, but MCs and 5-HT are 
probably involved.
Intestinal Infection and Inflammation
Intestinal infection has been considered as an important 
pathogenic factor in IBS, which may cause related bowel symp-
toms in a short period defined as PI-IBS. Many epidemiologic 
studies in China exhibited that the infection of dysentery was an 
independent risk factor for IBS.
68,69 A cohort study in Beijing fol-
lowed up patients after intestinal infection and healthy persons 
who had no previous history of functional bowel disorder. About 
8.1% of individuals with intestinal infection and 10.2% of those 
with Shigella infection were found to develop IBS in the 2-year-
period compared to only 0.8% in controls.
70 The incidence of 
PI-IBS has been reported to vary from 4% to 32% worldwide in a 
meta-analysis, with most about 10%, which was significantly 
higher than the IBS incidence in control group without infec-
tion.
71 Although intestinal infection was not specific for an area or 
a race, the types of microorganism infected on IBS patients were 
somewhat regional specific. Infections of Salmonella and Campy-
lobacter were always reported in the West,
71 while Shigella seemed 
to be a more usual bacterium in China and Korea from Asia.
70,72 
In Pakistan, Blastocystis hominis has been shown to be more com-
mon in IBS patients than healthy controls.
73 Although infections 
of parasites such as Giardia lamblia were common in some areas 
of Asia like India, there were few studies reporting their associa-
tion with IBS in Asia.
74 The different types of infected micro-
organism may be associated with the different resident environ-
ment and diet habits.
There were a lot of investigations suggesting the role of in-
flammation and immunity activation for IBS in China, most pre-
senting as the alteration of lymphocytes and cytokines (Table 4). 
Although conflicting results existed, decreased CD4/CD8 lym-
phocytes ratio was reported in IBS patients compared with 
controls.
75,76 Most investigations showed the immunity alteration 
in IBS patients with significantly higher level of proinflammatory 
cytokines (IL-1β,
77 IL-2,
78 IL-6,
79 IL-8,
80 IL-12,
81 IL-18,
79 
TNF-α,
80 IFN-γ
78,81) and lower level of anti-inflammatory cyto-
kines (IL-4,
82 IL-10
82,83), whether in peripheral blood or in in-
testinal mucosa. A study from Taiwan involving children sug-
gested anti-inflammatory cytokine IL-10 to negatively correlate 
with abdominal pain intensity,
83 implying the correlation between 
immune alteration and symptoms. Wu and Li et al
81,82 reported Pathophysiologic Findings of IBS in China
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Table 4. Studies on Inflammation for Irritable Bowel Syndrome in China
Targets First author Region Main findings
Lymphocytes Linghu and Yang
75 Peripheral blood Decreased CD4+ and increased CD8+ T lymphocytes with decreased 
CD4/CD8 ratio in IBS patients
Yang et al
76 Peripheral blood Decreased CD4+ and increased CD8+ T lymphocytes with decreased 
CD4/CD8 ratio in IBS-D patients; decreased CD4+ and CD8+ T 
lymphocytes with increased CD4/CD8 ratio in IBS-C patients
Fu et al
84 Intestinal mucosa/ Increased Th17 cells in colonic mucosa of IBS-D patients with nonspecific
  Peripheral blood   microscopic inflammation, but not in mucosa without inflammation and 
peripheral blood
Cytokines Zhang et al
80 Peripheral blood Higher IL-8 level in IBS-D patients, which positively correlated with TNF-α
level, but not found in IBS-C patients
Liang et al
79 Peripheral blood Higher IL-6 and IL-18 level in IBS-D patients; higher IL-18 level IBS-C 
patients; infection up-regulated IL-6 and IL-18 level
Hua et al
83 Peripheral blood Lower IL-10 level in IBS children, which negatively correlated with pain intensity
Ju et al
78 Intestinal mucosa Higher IL-2 and IFN-γ level in colonic and rectal mucosa in IBS-D patients
Song et al
77 Intestinal mucosa Higher IL-1β level at ICJ mucosa in IBS patients
Wu et al
82 Peripheral blood Significantly lower Th2-type cytokine level of IL-4 and IL-10 and relatively 
higher Th1-type cytokine level of IL-12 and IFN-γ in IBS-D patients, but not
in IBS-C patients
Li et al
81 Intestinal mucosa Significantly higher Th1-type cytokine level of IL-12 and IFN-γ and relatively 
lower Th2-type cytokine level of IL-4 and IL-10 in IBS-D patients 
Cytokines (PI-IBS) Wu et al
82  Peripheral blood Higher level of IFN-γ and lower level of IL-4 and IL-10 in post-infectious IBS-D
patients, but not in those without infection
Li et al
81 Intestinal mucosa Higher level of IL-12 and IFN-γ in post-infectious IBS-D patients, but not in 
those without infection
Ju et al
78 Intestinal mucosa SP in PI-IBS patients with positive expression of IL-2 and IFN-γ higher than that
in non-PI-IBS patients and controls
Wang et al
70 Intestinal mucosa Higher IL-1β mRNA expression in terminal ileum and recto-sigmoid junction in
PI-IBS patients than non-PI-IBS patients and controls
IBS, irritable bowel syndrome; IBS-C, constipation predominant IBS; IBS-D, diarrhea predominant IBS; ICJ, ileocecal junction; PI-IBS, post-infectious IBS; SP, 
substance P.
IBS-D patients had higher Th1-type cytokine level and lower 
Th2-type cytokine level in peripheral blood and intestinal 
mucosa.
2 Our group measured the Th1/Th2/Th17 level in pe-
ripheral blood and colonic mucosa for IBS-D patients, and 
showed Th17 proportion to be increased only in colonic mucosa 
with nonspecific microscopic inflammation, but not in the muco-
sa without inflammation and peripheral blood. There was no sig-
nificant change for the Th1, Th2 and associated cytokines be-
tween IBS patients and controls in either colonic mucosa or pe-
ripheral blood.
84 Moreover, PI-IBS patients were always found 
to have more severe inflammation than non-PI-IBS patients and 
healthy controls in China (Table 4).
70,78,81,82 It indicated that the 
role of intestinal infection for the pathogenesis of IBS probably 
acted through some immunological changes. 
The underlying mechanisms of PI-IBS have not been clearly 
identified worldwide. Persistent mucosal inflammation and im-
mune activation, manifested as increased lymphocytes, MCs, EC 
cells and inflammatory cytokines have been commonly reported 
in the West.
85 Similar to the results in China, there is also a trend 
toward higher level of proinflammatory cytokines and lower level 
of anti-inflammatory cytokines found in the investigations of oth-
er countries, although some conflicting results exist. Whether 
Th1-type or Th2-type profile is presented in IBS patients is still 
controversial with the contradictory results from different studies 
in the West.
86 Different from the results on lymphocytes in 
China, increased level of CD4+ and CD8+ T lymphocytes has 
always been reported in intestinal mucosa of IBS patients, while 
regular level was reported in peripheral blood.
87 The reasons for 
these different results are unclear, therefore additional inves-
tigations are needed. Anyway, all these studies above indicated 
that intestinal infection and inflammation might take part in the 
pathophysiology of IBS through immunological mechanism.Likun Zhong and Xiaohua Hou
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Food Hypersensitivity and Intolerance
Many patients with IBS always complained of their bowel 
symptoms relating to meal, implying some association between 
IBS and food. Although diet ingestion could affect symptoms 
through various pathways,
88 food hypersensitivity and intolerance 
were still considered as possible pathophysiologic factors for IBS. 
There were many studies reporting the levels of food-specific IgE 
and IgG antibodies in serum and the effectiveness of food elimi-
nation in China. Most studies reported that the levels of 
food-specific IgG antibody were higher in IBS patients than 
healthy controls.
89-92 Zuo et al
90 reported the serum IgG antibody 
titers of specific foods including shrimp, crab, soybean, egg and 
wheat, which were higher in patients with IBS, but there was no 
obvious association found between the IgG antibody titers and 
symptom severity. Zhang et al
89 showed that the frequency and 
severity of symptoms of IBS were obviously decreased in patients 
after eliminating intolerant foods based on IgG antibody for 8 
weeks. In the West, many studies have also displayed that serum 
IgG antibody levels were elevated in IBS patients,
93 and food 
elimination diets for the patients with increased IgG antibody to 
specific food antigens could help to reduce symptoms.
94 A sys-
tematic review of 7 clinical trials showed a 15%-71% response 
rate to diet exclusion, and the most commonly incriminated foods 
included milk, wheat and eggs.
95
Different from the IgG antibody, there is controversy for the 
results of food-specific IgE antibody in China. Xu and Zhu
91 re-
ported higher positive rate of food-specific IgE antibody in IBS 
patients than healthy individuals. Yang and Li
92 showed higher 
positive rate in IBS-D patients than controls, but not in IBS-C 
patients. No significant difference was found for food- specific 
and total IgE titers between IBS patients and healthy controls in 
another study by Zuo et al.
90 In the West, food-specific IgE level 
had been evaluated as one of the markers for food hyper-
sensitivity,
88 and there was little evidence for the role of IgE 
mediated immediate phase reaction in IBS.
96
Therefore most studies supported the role of food hyper-
sensitivity and intolerance in IBS, and diet exclusion based on 
IgG might be effective for treatment of IBS patients with elevated 
IgG level. However further investigations are needed to clarify 
the mechanisms underlying food hypersensitivity and intoler-
ance, and find more effective treatments for the patients with 
these problems.
Psychological Disturbances
Psychological disturbances occur commonly in IBS patients 
from both the Western or Eastern studies. Although psycho-
logical factor might not be the cause of IBS, it always correlated 
with the aggravation of symptoms. In China, many epidemiologic 
investigations showed that the IBS patients had more psycho-
logical problems.
61,97-101 A hospital-based investigation con-
ducted in 3 metropolises in China reported one quarter of pa-
tients with IBS had depressive or anxiety symptoms.
97 A recent 
large-scale study for undergraduates in Shandong province re-
ported the score of depression and anxiety by hospital anxiety and 
depression scale was higher in undergraduates diagnosed as IBS 
than healthy controls.
98 Our group also got the similar result for 
undergraduates in Wuhan.
99 Lee et al
100 showed IBS was closely 
related to generalized anxiety disorder in a community study of 
Hong Kong. Chen et al
61 found IBS patients who had more psy-
chological disturbance showed the increased number and de-
granulation of MCs in mucosa, implying the association between 
psychology and mucosal immunity alteration. Wang’s group
101 
reported that IBS patients paid more attention to GI symptoms 
and up-regulated visceral sensation under the stimulus of un-
comfortable pictures about digestive diseases, which were re-
lieved by diverting attention. Then this research not only showed 
the psychological disturbances in IBS patients but also displayed 
the effect of psychological factor on visceral hypersensitivity. In 
other studies, they showed the IBS patients had more negative life 
events and inappropriate coping styles,
102 and proposed the effec-
tiveness of cognitive therapy for the patients with refractory 
IBS.
103 There were also many other studies reporting that psy-
chotherapy was effective in the treatment of IBS,
104 which further 
supported that psychological factors played a role in pathogenesis 
of IBS. The association between IBS and psychological dis-
turbances has also been commonly reported in other countries. 
On the whole, psychological disturbances have been shown to be 
associated with IBS, but whether it is a pathophysiologic factor 
for IBS is still not certain. Hence much effort should be done to 
clarify the true relation between them and find out the underlying 
mechanisms. 
Altered Gut Microflora
It has been noticed that intestinal infection was related to IBS 
and antibiotics could affect digestive symptoms, which may in-
dicate the role of gut microflora in IBS. There were many studies 
reporting the changes in intestinal microflora in IBS patients and Pathophysiologic Findings of IBS in China
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the effectiveness of probiotics for them in China. An early study 
of our group examined 9 kinds of common microflora in feces, 
and showed that the number of Bacteroides, Bifidobacterium and 
Enterobacteria decreased in patients with IBS-D compared with 
that in healthy controls.
105 Si et al
106 found IBS patients had de-
creased number of Bifidobacterium and increased number of 
Enterobacteriaceae. The microbial colonization resistance, calcu-
lated as the ratio of Bifidobacterium to Enterobacteriaceae (B/E ra-
tio), was significantly lower in IBS patients (＜ 1) than that in 
controls (＞ 1), indicating impairment of colonization resistance 
and increased susceptibility to pathogenic bacteria overgrowth in 
IBS patients.
106 Chen et al
107 got the similar result for IBS-D pa-
tients, and they also reported decreased number of Lactobacillus 
and increased number of Saccharomycete. Zhang
108 found sig-
nificantly decreased number of anaerobic flora and increased 
number of aerobic flora in IBS patients and the dysbacteria state 
was different in distinct subtypes. However, the number of 
Bifidobacterium and Lactobacillus was always decreased in all sub-
types of IBS to varying degrees.
108
Although the results were different in various studies, most 
of the studies from China reported decreased level of Bifidobacte-
rium and Lactobacillus in IBS patients. Therefore targeted supple-
ment of probiotics containing these floras might be an effective 
therapeutic pathway. The benefits of probiotics to the improve-
ment of IBS symptoms have been commonly reported in numer-
ous studies in China.
109-112 A multi-center, double-blind, rando-
mized controlled trial exhibited the effect of Bifidobacterium for 
symptom improvement in IBS-D patients which was better than 
placebo group in all stages of the treatment.
109 Zhu et al
110 com-
pared the total and each symptom scores for IBS-D patients be-
fore and after the treatment with Medilac-S (Bacillus subtilis and 
Enterococcus faecium) and BIFICO (Bifidobacterium longum, Lacto-
bacillus acidophilus and Enterococcus), and showed the benefits of 
them. An open-label trial by Fan et al
111 reported that treatment 
with probiotics comprising Bifidobacterium, Lactobacillus and 
Enterococcus could regulate the balance of microorganism in intes-
tine and relieved the bowel symptoms of IBS. Zeng et al
112 
showed treatment with active lactic acid bacteria, which decreased 
the mucosal permeability of small bowel and achieved symptom 
improvement in IBS-D patients. The result implied that micro-
flora imbalance contributed to bowel symptoms of IBS through a 
pathway of changing the mucosal permeability.
112 To conclude, 
all these clinical studies in China showed that there was gut mi-
croflora alteration in patients with IBS and the treatment with 
probiotics probably improved the IBS symptoms by modulating 
the microorganism environments.
In the West, there were also a large amount of investigations 
exploring the microorganism states in IBS patients and the effects 
of different kinds of probiotics for patients. These researches 
didn’t exhibit concordant alterations of microflora among all IBS 
patients, while different microflora composition was found in dif-
ferent subtypes.
113 The underlying mechanisms for the role of 
microflora imbalance in IBS have not been clearly identified. 
Perhaps higher level of organic acid and excessive gas caused by 
altered intestinal flora, which was found to correlate with GI 
symptoms, would play a role in the pathophysiology of IBS.
113 
The therapeutic effect of probiotics varied in different studies for 
different strains chosen and trial designs. But a meta-analysis of 
these studies confirmed the benefit of probiotics in the treatment 
of IBS.
114 However, probiotics cannot be effective for all IBS pa-
tients, so further work is deserved to identify the patient groups 
which can get most benefit from it and to choose the most appro-
priate and effective strains.
Conclusion
The factors discussed above have been displayed to be asso-
ciated with the pathophysiology of IBS. Although most of the re-
sults of related investigations in China were similar to the Western 
and other Eastern countries, it was needed to pay more attention 
that some conflicting outcomes existed in China. Since IBS is a 
heterogeneous disorder, it is probable that more than one mecha-
nism to be presented in a specific patient and these particular 
mechanisms are involved in different patients to various extents. 
IBS still remains a complicated and inadequately understood 
disease. So much effort is needed in future to get a better under-
standing about the pathophysiology for symptom generation and 
to develop more effective and appropriate therapy for IBS.
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